BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17555394)

  • 1. Risk-benefit trade-offs and precision utilities in phase I-II clinical trials.
    Msaouel P; Lee J; Thall PF
    Clin Trials; 2024 Jun; 21(3):287-297. PubMed ID: 38111231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Aktuelle Urol; 2024 Jun; 55(3):198-201. PubMed ID: 38806032
    [No Abstract]   [Full Text] [Related]  

  • 3. [First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis].
    Kunath F
    Urologie; 2024 Apr; 63(4):379-382. PubMed ID: 38478073
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic challenges in advanced renal cell carcinoma.
    Cho DC
    Clin Pract (Lond); 2013 Jan; 10(1):39-46. PubMed ID: 23378893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic non-clear cell renal cell carcinoma: current therapeutic options.
    Schrader AJ; Olbert PJ; Hegele A; Varga Z; Hofmann R
    BJU Int; 2008 Jun; 101(11):1343-5. PubMed ID: 18241246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and prognosis in advanced renal cell carcinoma.
    Galsky MD; Vogelzang NJ
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):839-45. PubMed ID: 17555394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.